PReS-FINAL-2180: Efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH
نویسندگان
چکیده
PReS-FINAL-2180: Efficacy and safety of tocilizumab (TCZ) in patients with polyarticularcourse juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH F De Benedetti, N Ruperto, Z Zuber, R Cuttica, R Xavier, I Calvo, N Rubio, E Alekseeva, V Chasnyk, J Chavez, G Horneff, V Opoka-Winiarska, P Quartier, A Spindler, C Keane, K Bharucha, J Wang, D Lovell, A Martini, HI Brunner, PRINTO and PRCSG
منابع مشابه
PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
Introduction TCZ, an IL-6R inhibitor, is effective in systemic and polyarticular juvenile idiopathic arthritis (sjia, pjia). BWadjusted, intravenous dosing regimens (TCZ8 mg/kg Q2W for sjia and Q4W for pjia) were assessed in Japanese phase 3 trials. As shown in Results, BW adjustment led to lower TCZ exposure with lower BW; thus, higher doses were proposed for patients (pts) with BW<30 kg in th...
متن کاملPReS-FINAL-2070: Efficacy of biologic treatments in juvenile idiopathic arthritis with a polyarticular course: an indirect comparison
Methods Based on a literature review, we identified RCTs of abatacept, adalimumab (ADA), etanercept, infliximab and tocilizumab (TCZ) in pcJIA. Comparative effectiveness was estimated on the reported American College of Rheumatology response rates (JIA ACR30/50/70/90) measured at the end of the randomised, double-blind phase by means of a Bayesian indirect comparison using a fixed-effects order...
متن کاملPReS-FINAL-2134: Assessment of radiographic progression in patients (pts) with systemic juvenile idiopathic arthritis (sjia) treated with tocilizumab (TCZ): 2-year results from the tender trial
PReS-FINAL-2134: Assessment of radiographic progression in patients (pts) with systemic juvenile idiopathic arthritis (sjia) treated with tocilizumab (TCZ): 2-year results from the tender trial C Malattia, N Ruperto, E Palmisani, S Pederzoli, A Pistorio, HI Brunner, R Cuttica, I Calvo, SM Garay, D Eleftheriou, C Wouters, J Wang, C Devlin, D Lovell, A Martini, F De Benedetti, A Ravelli, PRCSG an...
متن کاملEfficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial
OBJECTIVE To evaluate the interleukin-6 receptor inhibitor tocilizumab for the treatment of patients with polyarticular-course juvenile idiopathic arthritis (pcJIA). METHODS This three-part, randomised, placebo-controlled, double-blind withdrawal study (NCT00988221) included patients who had active pcJIA for ≥6 months and inadequate responses to methotrexate. During part 1, patients received ...
متن کاملPReS-FINAL-2166: Long-term safety and effectiveness of anti-interleukin-6 receptor monoclonal antibody, tocilizumab, in patients with systemic juvenile idiopathic arthritis in Japan
Introduction Systemic-onset juvenile idiopathic arthritis (sjia) is a form of childhood chronic arthritis of unknown etiology with systemic manifestations such as remittent fever and erythematous rash, lymph adenopathy, hepatosplenomegaly, and/or serositis. Tocilizumab (TCZ) is a humanized anti-IL-6 receptor monoclonal antibody that has been approved for the treatment of patients with sjia. Res...
متن کامل